{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-24-000080","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.007742+00:00","generated_at":"2026-05-30T04:35:53.189471+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Caribou Q3 net loss $34.7M vs $10.0M YoY; cash $281M funds into H2 2026","bullets":["Revenue $2.0M, down from $23.7M due to AbbVie termination; R&D expense $30.4M.","Cash & equivalents $281M as of Sept 30, 2024, down from $372.4M at Dec 31, 2023.","CB-010 lupus GALLOP Phase 1 trial initiation expected by year-end 2024; Fast Track granted.","CB-011 CaMMouflage dose escalation data for r/r MM expected H1 2025; no DLTs observed.","Tina Albertson, MD/PhD, appointed CMO in August 2024; led BREYANZI development."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-24-000080","json":"https://secwatch.observer/filing/0001619856-24-000080.json","markdown":"https://secwatch.observer/filing/0001619856-24-000080.md","text":"https://secwatch.observer/filing/0001619856-24-000080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985624000080/0001619856-24-000080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985624000080/crbu-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:35:53.189471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}